ImmunityBio (NASDAQ:IBRX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research report report published on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $30.00 price objective on the stock.

A number of other equities research analysts also recently commented on IBRX. BTIG Research began coverage on shares of ImmunityBio in a research report on Friday, January 10th. They issued a “buy” rating and a $6.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of ImmunityBio in a research report on Thursday, March 13th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.19.

ImmunityBio Price Performance

Shares of NASDAQ:IBRX opened at $2.78 on Tuesday. ImmunityBio has a 1 year low of $2.28 and a 1 year high of $10.53. The company has a market cap of $2.37 billion, a P/E ratio of -3.02 and a beta of 0.51. The stock’s fifty day moving average price is $3.00 and its 200-day moving average price is $3.52.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.11. The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $8.74 million. On average, sell-side analysts anticipate that ImmunityBio will post -0.92 earnings per share for the current year.

Institutional Trading of ImmunityBio

Hedge funds have recently bought and sold shares of the stock. Courier Capital LLC raised its stake in shares of ImmunityBio by 33.3% in the first quarter. Courier Capital LLC now owns 40,000 shares of the company’s stock worth $120,000 after buying an additional 10,000 shares during the period. Thrive Wealth Management LLC bought a new stake in ImmunityBio during the 1st quarter worth approximately $30,000. Rhumbline Advisers lifted its holdings in ImmunityBio by 5.6% during the first quarter. Rhumbline Advisers now owns 219,360 shares of the company’s stock valued at $660,000 after purchasing an additional 11,573 shares in the last quarter. Collective Family Office LLC boosted its position in shares of ImmunityBio by 17.3% in the first quarter. Collective Family Office LLC now owns 104,170 shares of the company’s stock worth $314,000 after purchasing an additional 15,340 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of ImmunityBio in the fourth quarter worth $37,000. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.